Employment status at time of acute myocardial infarction and risk of death and recurrent acute myocardial infarction.

Employment status Epidemiology Mortality Myocardial infarction Recurrent myocardial infarction

Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
09 05 2023
Historique:
received: 23 10 2022
revised: 12 12 2022
accepted: 13 12 2022
medline: 11 5 2023
pubmed: 19 1 2023
entrez: 18 1 2023
Statut: ppublish

Résumé

Employment is important for physical and mental health and self-esteem and provides financial independence. However, little is known on the prognostic value of employment status prior to admission with acute myocardial infarction (MI). Using Danish nationwide registries, all patients between 18 and 60 years with a first-time MI admission (2010-2018) and alive at discharge were included. Rates of all-cause mortality and recurrent MI according to workforce attachment at the time of the event was compared using multivariable Cox regression. Of the 16 060 patients included in the study, 3520 (21.9%) patients were not part of the workforce. Patients who were not part of the workforce were older (52 vs. 51 years), less often men (63% vs. 77%), less likely to have higher education, more often living alone (47% vs. 29%), and more often had comorbidities, including heart failure, atrial fibrillation, hypertension, diabetes, chronic kidney disease, and chronic obstructive pulmonary disease. The absolute 5-year risk of death was 3.3% and 12.8% in the workforce and non-workforce group, respectively. The corresponding rates of recurrent MI were 7.5% and 10.9%, respectively. In adjusted analyses, not being part of the workforce was associated with a significantly higher rate of all-cause mortality [HR: 2.39 (95% CI: 2.01-2.83)] and recurrent MI [1.36 (1.18-1.57)]. Among patients of working age who were admitted with MI and alive at discharge, not being part of the workforce was associated with a higher long-term rate of all-cause mortality and recurrent MI. In patients of working age admitted with a heart attack, not being part of the workforce was associated with an increased risk of mortality and new heart attacks following discharge, as compared with patients being part of the workforce. Key findings As compared with patients being part of the workforce, patients who were not part of the workforce had an increased risk of mortality following discharge.As compared with patients being part of the workforce, patients who were not part of the workforce had an increased risk of a new heart attack following discharge.

Sections du résumé

BACKGROUND
Employment is important for physical and mental health and self-esteem and provides financial independence. However, little is known on the prognostic value of employment status prior to admission with acute myocardial infarction (MI).
METHODS AND RESULTS
Using Danish nationwide registries, all patients between 18 and 60 years with a first-time MI admission (2010-2018) and alive at discharge were included. Rates of all-cause mortality and recurrent MI according to workforce attachment at the time of the event was compared using multivariable Cox regression. Of the 16 060 patients included in the study, 3520 (21.9%) patients were not part of the workforce. Patients who were not part of the workforce were older (52 vs. 51 years), less often men (63% vs. 77%), less likely to have higher education, more often living alone (47% vs. 29%), and more often had comorbidities, including heart failure, atrial fibrillation, hypertension, diabetes, chronic kidney disease, and chronic obstructive pulmonary disease. The absolute 5-year risk of death was 3.3% and 12.8% in the workforce and non-workforce group, respectively. The corresponding rates of recurrent MI were 7.5% and 10.9%, respectively. In adjusted analyses, not being part of the workforce was associated with a significantly higher rate of all-cause mortality [HR: 2.39 (95% CI: 2.01-2.83)] and recurrent MI [1.36 (1.18-1.57)].
CONCLUSION
Among patients of working age who were admitted with MI and alive at discharge, not being part of the workforce was associated with a higher long-term rate of all-cause mortality and recurrent MI.
In patients of working age admitted with a heart attack, not being part of the workforce was associated with an increased risk of mortality and new heart attacks following discharge, as compared with patients being part of the workforce. Key findings As compared with patients being part of the workforce, patients who were not part of the workforce had an increased risk of mortality following discharge.As compared with patients being part of the workforce, patients who were not part of the workforce had an increased risk of a new heart attack following discharge.

Autres résumés

Type: plain-language-summary (eng)
In patients of working age admitted with a heart attack, not being part of the workforce was associated with an increased risk of mortality and new heart attacks following discharge, as compared with patients being part of the workforce. Key findings As compared with patients being part of the workforce, patients who were not part of the workforce had an increased risk of mortality following discharge.As compared with patients being part of the workforce, patients who were not part of the workforce had an increased risk of a new heart attack following discharge.

Identifiants

pubmed: 36653331
pii: 6991767
doi: 10.1093/eurjpc/zwad013
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

572-580

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflict of interest: J.H.B.: Advisory board honoraria from Bayer; consultant honoraria from Novartis and AstraZeneca; travel grants from AstraZeneca; C.T.-P.: Grants for studies from Bayer and Novo Nordisk; L.K.: Speakers honorarium from Novo, Novartis, AstraZeneca and Boehringer; E.L.F.: Independent research grant from novo nordisk foundation.

Auteurs

Jeppe K Petersen (JK)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Abdulrahman N Shams-Eldin (AN)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Emil L Fosbøl (EL)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Rasmus Rørth (R)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Rikke Sørensen (R)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Reza Jabbari (R)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Thomas Engstrøm (T)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Lene Holmvang (L)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Frants Pedersen (F)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Amna Alhakak (A)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Johanna Krøll (J)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Christian Torp-Pedersen (C)

Department of Cardiology, Nordsjællands Hospital, Dyrehavevej 29, 3400 Hillerød, Denmark.
Department of Cardiology, Aalborg University Hospital, Hobrovej 18-22, 9000 Aalborg, Denmark.
Department of Public Health, University of Copenhagen, Øster Farimagsgade 5, 1353 Copenhagen, Denmark.

Lars Køber (L)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Jawad H Butt (JH)

Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH